molecular imaging

Molecular imaging demonstrates promise for predicting complete pathologic response in HER2-positive breast cancer

Molecular imaging with 68Ga-HER2 PETCT may provide an early, targeted measure of how well treatment is working in patients with HER2-positive breast cancer. According to new research published in the October issue of The Journal of Nuclear Medicine, 68Ga-HER2 PETCT can detect changes in HER2-positive breast cancer after only two cycles of neoadjuvant treatment, enabling […]

Read More

Imaging study indicates 99mTc-maraciclatide is a promising diagnostic and monitoring tool for endometriosis

Serac Healthcare, a clinical radiopharmaceutical company developing the molecular imaging agent 99mTc-maraciclatide, and the Nuffield Department of Women’s and Reproductive Health at the University of Oxford have had phase 2 data published from the DETECT (Detecting endometriosis expressed integrins using technetium-99m) imaging study. Published online in The Lancet Obstetrics, Gynaecology & Women’s Health, the study […]

Read More